Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105 (Q35671356)
Jump to navigation
Jump to search
scientific article published on 6 April 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105 |
scientific article published on 6 April 2015 |
Statements
1 reference
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105 (English)
1 reference
James M Ford
1 reference
Joseph A Sparano
1 reference
Allison W Kurian
1 reference
Melinda L Telli
1 reference
Kristin C Jensen
1 reference
Shaveta Vinayak
1 reference
Jafi A Lipson
1 reference
Patrick J Flaherty
1 reference
Kirsten Timms
1 reference
Victor Abkevich
1 reference
Elizabeth A Schackmann
1 reference
Irene L Wapnir
1 reference
Robert W Carlson
1 reference
Pei-Jen Chang
1 reference
Bobbie Head
1 reference
Lori J Goldstein
1 reference
Barbara Haley
1 reference
Shaker R Dakhil
1 reference
Julia E Reid
1 reference
Anne-Renee Hartman
1 reference
Judith Manola
1 reference
1 reference
1 reference
Identifiers
1 reference